Quantcast

Latest Most Up-to-Date Cancer Personalized Medicine Market Report

July 16, 2008

Research and Markets (http://www.researchandmarkets.com/research/97032f/cancer_personalize) has announced the addition of the “Cancer Personalized Medicine 2008″ report to their offering.

This is the latest most up-to-date Cancer Personalized Medicine Market Report. This report presents an up-to-date and thorough analysis of the Cancer Personalized Medicine Marketplace based upon our continuing industry coverage. Personalized Medicine, especially as it relates to Cancer, is undergoing significant growth and this report focuses in on the science, market/commercialization, and diagnostic/therapeutics trends in this space.

The Cancer Personalized Medicine marketplace represents the paradigm for personalized medicine market evolution and we focus in this report on the various commercialized cancer predictor tests, their current status, traction in the marketplace, quantitative market opportunities, and the factors that are driving as well as challenging the expansion of this space.

Emerging classes of cancer biomarkers such as microRNAs and epigenetics are also examined in this report as well as the pipeline of RNAi-therapeutics for cancer. These biomarkers and treatment methodologies are drivers of the growth of the cancer personalized medicine marketplace for the future and therefore we provide coverage of these areas in this report–together with market participants making an impact in these particular areas.

Personalized Medicine marketplace is part of our continuous industry tracking and as part of this coverage; this report presents comprehensively the cancer personalized medicine market landscape in terms of:

— Cancer Diagnostic Tests on the marketplace and in development that are developed as companion-diagnostics (coupled with a therapeutic regimen)

— Landscape of In Vitro Diagnostic Multivariate Index Assays (IVDMIAs)–multigene predictors with prognostic/predictive value

— Key Personalized Medicine Products in the Breast Cancer, Colon Cancer, etc. market spaces–together with the characteristics/features of These Products–HER2, oncotype DX(TM), MammaPrint(R), UGT1A1, K-RAS, EGFR, etc.

— Worldwide market survey completed recently–June 2008–of qualitative and quantitative market trends/metrics in this space. Report purchasers receive access to all the raw data from the market survey via access to a secure server as well as all the annotated/analyzed data in the report. This highly valuable and recently collected dataset is based on an extensive market analysis. Industry Analyst Team–all the raw data and analyses based on the data are presented in the report

— Quantitative market forecast–for the year 2008 through 2011

— Comprehensive profiles of the various market participants in this space

— All report purchasers are entitled to 1 hour of free consultation with our Industry Analysts

This report also includes an overview of the drug metabolism and toxicity process, the role of specific cytochrome P450 (CYP450) enzymes, and how these impact personalized medicine.

Furthermore, in this report are presented an overview of the FDA-regulatory process on In Vitro Diagnostic Multivariate Index Assays (IVDMIAs), and how this impacts the market acceptance of the various cancer personalized medicine tests either in development or out in the market.

Key Topics Covered:

Chapter I. Executive Overview of the Space

— Molecular Diagnostics in Cancer: Breakout of the Market By Types of Tests and Their Value Proposition

— Prognostic vs. Predictive Markers for Cancer

— Personalized Medicine is Driving Cancer Treatment Decisions TODAY

— Commercialization Metrics: Drugs vs. Diagnostics

— The Lopsided Remuneration for Diagnostics: Personalized Medicine is Changing This Paradigm

— Trajectory of Genomics-based Cancer Biomarker Tests, such as IVDMIAs, for Personalized Medicine and Drivers for Market Acceptance

— Trajectory of Genomics-based Cancer Biomarker Tests, such as IVDMIAs, for Personalized Medicine: Drivers and Challenges

— Quantitative Market Metrics: Market Sizes

— The Future of Cancer Personalized Medicine 5-16

Chapter II. Emerging Cancer Biomarkers for Personalized

Medicine: microRNA-based, Epigenetics-based

— Potential Role of microRNAs and Epigenetics in Cancer Personalized Medicine–The Potential Market Opportunities

— A microRNA Cancer Map

— microRNAs that are Associated with Human Cancers

— microRNAs that may Regulate Cancer-related Genes – I

Particular microRNAs may regulate specific cancer genes & their effect on cell function

— microRNAs that may Regulate Cancer-related Genes – II. Alteration of microRNA expression in human malignancies

— Epigenetic Alterations in Cancer

— Predicted Impact of microRNA Diagnostics on Various Disease Areas and Associated Timelines

— Predicted Impact of microRNA Therapeutics on Various Disease Areas and Associated Timelines

— Rosetta Genomics Ltd., A Pioneer in Developing and Commercializing microRNA-based Cancer Diagnostics

— Selected Market Participants Developing Epigenetics-based Cancer Personalized Tests

Chapter III. RNAi Therapeutics Landscape for Cancer 32-37

Chapter IV. Market Analysis: Cancer Personalized Medicine

— Why Cancer Personalized Medicine?

Value Delivered by the Diagnostic and Associated Value by the Therapeutic

— Cancer Personalized Medicine:Anticancer drugs that can be used together with a pharmacodiagnostic test

— Economics of Cancer Personalized Medicine

— Multigene Predictors of Clinical Outcome for Breast Cancer

— Comparison of Cost of Tests Across the Market Landscape for Breast Cancer Testing

— Personalized Medicine in Other Cancers–A Complete Analysis of the Entire Landscape

— Personalized Warfarin Therapy: Another Paradigm for the Personalized Medicine Marketplace

— Cancer Personalized Medicine Worldwide Market Survey Data 38-106

Chapter V. Industry Participants in Personalized Medicine

 - Abbott Molecular - Affymetrix - Agendia BV - Celera - Cepheid - Clinical Data: PGXHealth, Cogenics, and Epidauros - Dako Denmark A/S - deCODE genetics - DNA Direct - DxS Ltd. - Exact Sciences - eXagen Diagnostics - Gen-Probe - Genelex - Genentech - Genomic Health - Genzyme Genetics - Illumina - Luminex - Monogram Biosciences - Myriad Genetics - Nanogen - Osmetech Molecular Diagnostics - Perlegen Sciences - PGxI Laboratories - Prometheus Laboratories - Roche Diagnostics - Siemens Medical Solutions Diagnostics - Target Discovery - Third Wave Technologies - XDx - Ventana Medical Systems/Roche 

Companies Mentioned:

 - Abbott Molecular - Affymetrix - Agendia BV - Celera - Cepheid - Clinical Data: PGXHealth, Cogenics, and Epidauros - Dako Denmark A/S - deCODE genetics - DNA Direct - DxS Ltd. - Exact Sciences - eXagen Diagnostics - Gen-Probe - Genelex - Genentech - Genomic Health - Genzyme Genetics - Illumina - Luminex - Monogram Biosciences - Myriad Genetics - Nanogen - Osmetech Molecular Diagnostics - Perlegen Sciences - PGxI Laboratories - Prometheus Laboratories - Roche Diagnostics - Siemens Medical Solutions Diagnostics - Target Discovery - Third Wave Technologies - Ventana/Roche - XDx 

For more information visit http://www.researchandmarkets.com/research/97032f/cancer_personalize




comments powered by Disqus